| Literature DB >> 24461907 |
Tobias B Haack1, Matteo Gorza2, Katharina Danhauser1, Johannes A Mayr3, Birgit Haberberger4, Thomas Wieland2, Laura Kremer2, Valentina Strecker5, Elisabeth Graf2, Yasin Memari6, Uwe Ahting4, Robert Kopajtich2, Saskia B Wortmann7, Richard J Rodenburg7, Urania Kotzaeridou8, Georg F Hoffmann8, Wolfgang Sperl3, Ilka Wittig5, Ekkehard Wilichowski9, Gudrun Schottmann10, Markus Schuelke10, Barbara Plecko11, Ulrich Stephani12, Tim M Strom1, Thomas Meitinger1, Holger Prokisch1, Peter Freisinger13.
Abstract
Defects of mitochondrial oxidative phosphorylation (OXPHOS) are associated with a wide range of clinical phenotypes and time courses. Combined OXPHOS deficiencies are mainly caused by mutations of nuclear genes that are involved in mitochondrial protein translation. Due to their genetic heterogeneity it is almost impossible to diagnose OXPHOS patients on clinical grounds alone. Hence next generation sequencing (NGS) provides a distinct advantage over candidate gene sequencing to discover the underlying genetic defect in a timely manner. One recent example is the identification of mutations in MTFMT that impair mitochondrial protein translation through decreased formylation of Met-tRNA(Met). Here we report the results of a combined exome sequencing and candidate gene screening study. We identified nine additional MTFMT patients from eight families who were affected with Leigh encephalopathy or white matter disease, microcephaly, mental retardation, ataxia, and muscular hypotonia. In four patients, the causal mutations were identified by exome sequencing followed by stringent bioinformatic filtering. In one index case, exome sequencing identified a single heterozygous mutation leading to Sanger sequencing which identified a second mutation in the non-covered first exon. High-resolution melting curve-based MTFMT screening in 350 OXPHPOS patients identified pathogenic mutations in another three index cases. Mutations in one of them were not covered by previous exome sequencing. All novel mutations predict a loss-of-function or result in a severe decrease in MTFMT protein in patients' fibroblasts accompanied by reduced steady-state levels of complex I and IV subunits. Being present in 11 out of 13 index cases the c.626C>T mutation is one of the most frequent disease alleles underlying OXPHOS disorders. We provide detailed clinical descriptions on eleven MTFMT patients and review five previously reported cases.Entities:
Keywords: Exome sequencing; Leigh syndrome; MTFMT; Mitochondrial translation; OXPHOS deficiency
Mesh:
Substances:
Year: 2013 PMID: 24461907 DOI: 10.1016/j.ymgme.2013.12.010
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797